Loading...
XNASSILO
Market cap2mUSD
Dec 24, Last price  
0.92USD
1D
4.15%
1Q
-12.37%
IPO
-96.39%
Name

Silo Pharma Inc

Chart & Performance

D1W1MN
XNAS:SILO chart
P/E
—
P/S
40.31
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
25.68%
Rev. gr., 5y
%
Revenues
72k
0.00%
00105,522-107,114-145,185-669,480847,407040,56940,92371,26472,10272,102
Net income
-4m
L-5.32%
-49,803-39,44632,911-376,549-409,498-1,112,974356,536-969,463-1,048,086-3,129,8653,903,741-3,908,551-3,700,683
CFO
-3m
L-7.81%
-46,303-21,473-181,609-1,062,960-1,016,756-143,555-284,618272,637-794,324-1,156,996-2,278,016-3,497,622-3,224,498
Earnings
Mar 24, 2025

Profile

URL
https://silopharma.com/
IPO date
Jan 05, 2012
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
72
0.00%
72
1.18%
71
74.14%
Cost of revenue
3,928
2,450
2,964
Unusual Expense (Income)
NOPBT
(3,856)
(2,378)
(2,893)
NOPBT Margin
Operating Taxes
1
25
Tax Rate
NOPAT
(3,856)
(2,379)
(2,918)
Net income
(3,701)
-5.32%
(3,909)
-200.12%
3,904
-224.73%
Dividends
Dividend yield
Proceeds from repurchase of equity
(471)
4,941
3,794
BB yield
10.62%
-64.38%
-27.76%
Debt
Debt current
(364)
(418)
Long-term debt
Deferred revenue
794
866
938
Other long-term liabilities
Net debt
(7,665)
(11,734)
(10,736)
Cash flow
Cash from operating activities
(3,224)
(3,498)
(2,278)
CAPEX
Cash from investing activities
(4,147)
87
7,193
Cash from financing activities
(471)
4,941
3,794
FCF
(3,856)
(2,379)
(2,747)
Balance
Cash
7,665
11,370
10,257
Long term investments
61
Excess cash
7,662
11,367
10,315
Stockholders' equity
(10,878)
(7,171)
(3,253)
Invested Capital
17,848
18,013
12,835
ROIC
ROCE
EV
Common stock shares outstanding
3,080
2,284
1,918
Price
1.44
-57.14%
3.36
-52.84%
7.13
-66.42%
Market cap
4,435
-42.22%
7,675
-43.85%
13,669
-51.17%
EV
(3,230)
(4,059)
2,933
EBITDA
(3,766)
(2,378)
(2,785)
EV/EBITDA
0.86
1.71
Interest
5
2
3
Interest/NOPBT